ReviewCurrent cardiology reports2026
Ventricular Assist Device Use in Single Ventricle Heart Disease: Current Outcomes and Considerations.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHeart failure in patients with congenital heart disease and particularly single ventricle physiology at all stages of palliation presents significant management challenges. Ventricular assist device (VAD) use in this population is increasing. This review summarizes the recent outcomes, physiologic considerations, and challenges of VAD therapy at each stage of single ventricle palliation. RECENT
findingsSurvival after VAD implantation has been worse for patients with single ventricle physiology compared with biventricular physiology, though recent data suggest this disparity is narrowing. A variety of continuous and pulsatile flow devices are available for use, though many are not approved by the Food and Drug Administration for use in the pediatric population. Adverse effects are common with VADs at each stage of single ventricle palliation, regardless of device choice. VAD therapy in patients with single ventricle heart disease requires an understanding of the complex cardiac physiology and device mechanics in order to optimize outcomes.
Indexed as
Identifiers
42530716What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.